First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

Authors

Fengzhuo Cheng (ORCID: https://orcid.org/0000-0003-1367-252X)
Chengzhi Zhou (ORCID: https://orcid.org/0000-0003-0029-6879)
Fenglin She
Likun Chen (ORCID: https://orcid.org/0000-0002-7158-3878)
Guowu Wu (ORCID: https://orcid.org/0000-0001-6449-4861)
Haibo Zhang (ORCID: https://orcid.org/0000-0002-5134-4167)
Xue Hou (ORCID: https://orcid.org/0000-0002-5552-7569)
Lin Wen (ORCID: https://orcid.org/0000-0003-4921-6147)
Jiqun Yi
Jingye Lv
Zhanhong Xie

Institutions

Guangzhou University of Chinese Medicine (CN)
Sun Yat-sen University (CN)
Shantou University (CN)
Meizhou City People's Hospital (CN)
Cancer Hospital of Shantou University Medical College (CN)
First Affiliated Hospital of Guangzhou Medical University (CN)
Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
Twelfth Guangzhou City People's Hospital (CN)
Sun Yat-sen University Cancer Center (CN)
Jiangsu Hengrui Medicine (China) (CN)
State Key Laboratory of Respiratory Disease (CN)
Guangzhou Medical University (CN)

Publication Details

Journal: EClinicalMedicine
Published: 2025-11-15
DOI: https://doi.org/10.1016/j.eclinm.2025.103638
Citations: 1
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 1.52

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

Fengzhuo Cheng, Chengzhi Zhou, Fenglin She, Likun Chen et al.

Nov 15, 2025

1 citations

EClinicalMedicine

Lung Cancer Treatments and Mutations

1.52

article

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

Fengzhuo Cheng, Chengzhi Zhou, Fenglin She, Likun Chen, Guowu Wu, Haibo Zhang, Xue Hou, Lin Wen, Jiqun Yi, Jingye Lv, Zhanhong Xie

November 15, 2025article en

1 citations

Abstract

No abstract available for this paper.

EClinicalMedicineVol. 90

Guangzhou University of Chinese Medicine (CN), Sun Yat-sen University (CN), Shantou University (CN), Meizhou City People's Hospital (CN), Cancer Hospital of Shantou University Medical College (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Guangdong Provincial Hospital of Traditional Chinese Medicine (CN), Twelfth Guangzhou City People's Hospital (CN), Sun Yat-sen University Cancer Center (CN), Jiangsu Hengrui Medicine (China) (CN), State Key Laboratory of Respiratory Disease (CN), Guangzhou Medical University (CN)

Openalex Percentile: Top 13%

Lung Cancer Treatments and Mutations

1.52

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China — Fengzhuo Cheng, Chengzhi Zhou, et al. · EClinicalMedicine (2025) | TGRS Research Map | TGRS